pharma_pill_manufacturing

Valeant plots significant investment in Canadian operations

pharmafile | June 20, 2016 | News story | Manufacturing and Production, Sales and Marketing Canada, Valeant, manufacturing 

Valeant Pharmaceuticals (NYSE: VRX) has announced that it plans to expand its Canadian operations with a $27.5 million expansion of its manufacturing and export capacity at its sites in Steinbach, Manitoba and Laval, Quebec.

Its Steinbach expansion will see $7 million in upgrades to its product manufacturing technology and $8 million for the transfer of North American production of Xifaxan (rixafimin) and Apriso (mesalamine). In Laval, $10 million will go towards upgrading product manufacturing technology while $2.5 million will facilitate the transfer of production of Arestin (minocycline hydrochloride) to the facility.

These moves form parts of Valeant’s wider move towards Canadian operations, which has seen it transfer 27 technologies to Steinbach manufacturing and produce 67 new products at its Laval facility since 2012.

Advertisement

Valeant CEO, Joseh Papa, says: “Our investments reflect our ongoing commitment to growing our operational presence and export capacity in Canada. These facilities play a critical role in advancing healthcare technology both in Canada, and around the globe, and we are proud to take on an even larger role in further bolstering Canada’s life sciences economy.”

Sean Murray

Related Content

Canada awards CSL Seqirus with influenza pandemic vaccine contract

CSL Seqirus has been awarded a contract committing it to manufacturing and delivering influenza vaccines …

BioDuro establishes joint manufacturing venture with Cenra

BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with …

CARBOGEN AMCIS manufacturing license advances services in China

Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

The Gateway to Local Adoption Series

Latest content